Search
for

    Learn

    5 / 801 results

      learn SCUBE3

      a signaling molecule from dermal papilla cells being actively researched

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

      learn Tofacitinib

      a JAK inhibitor for alopecia areata and other autoimmune conditions

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Finally live! alcohol-free, propylene glycol–free topical finasteride foam

      in Update  15 upvotes 7 months ago
      A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

      community Disappointing news on Breezula/CB-03-01

       22 upvotes 7 years ago
      The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 11 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.